Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that ER positive, HER2-positive, PR positive status confers therapeutic sensitivity to Neratinib in patients with Invasive Breast Carcinoma.
This statement is based on a regulatory approval from the Health Canada:
NERLYNX (neratinib) is indicated for the extended adjuvant treatment of women with early-stage hormone receptor positive and HER2-overexpressed/amplified breast cancer, within one year after completion of trastuzumab-based adjuvant therapy.